STAT Plus: Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results By Elizabeth Cooney. Health. Health June 20, 2025.

Source Reference: Good SD, et al "A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy" Lancet Rheumatol 2025; DOI: 10.1016/S2665-9913(25)00100-6.

VX-264 and zimislecel came from Vertex’s 2019 acquisition of privately held Semma Therapeutics. The $950 million deal established Vertex’s presence in type 1 diabetes therapy R&D. In 2022 ...

By using stem cell therapy, scientists and clinicians aim not only to slow disease progression—but to restore lost functions and improve quality of life. In MS, for example, ...

Doctors and specialists at the Murdoch Children's Research Institute in Melbourne, Australia, are studying and reprogramming the potential of the blood to treat heart failure in children.

A faster, simpler, cheaper cancer cell therapy is about to be tested in humans. By Jason Mast July 9, 2024. Reprints. CAR-T cell therapy in multiple myeloma. Adobe.

Pressure to make cell and gene therapies more affordable will force the industry to overcome its reticence and embrace closed production systems, automation, and artificial intelligence (AI). So ...

CAR-T cell therapy for hematologic cancers is now available at St. George Regional Hospital. Jacqueline, a Las Vegas patient who traveled to Salt Lake City for the treatment, said it saved her life.

Promising cell therapy offers hope for relapsed or refractory T-cell leukaemia. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 10 / 241007115451.htm ...

New gene therapy improves the life of 18-year-old with Sickle Cell Disease which affects 5,000 New Jersey residents living with the condition. Skip to Article Set weather ...

Expert speakers break down the science behind CAR cell therapy and T-cell engagers, explain the clinical trial process, and discuss potential benefits and risks. Whether you’re living with lupus, ...

Aaron Scott, of Fayetteville, is the first in North Carolina to receive a new FDA-approved therapy which uses the patient's own cells to relieve the pain of sickle cell disease.